Topics

Effects of a Self-regulation Program on Self-care Behaviour of Heart Failure Patients

2020-01-19 11:04:54 | BioPortfolio

Summary

This RCT study aims to examine the effects of a self-regulation programme on the self-care behaviour and quality of life of patients with heart failure. The following hypothesis was tested: Heart failure patients who receive the self-regulation program will report significant improvements in self-care behaviours after four weeks of the self-regulation programme. In contrast, patients in the control group showed no significant differences.

Description

Eight two patients with heart failure were randomly assigned into the intervention (n = 41) or control group (n = 41). The intervention group participated in a 4-week self-regulation programme, including 20 to 30 minutes of individual self-regulation education and 15 to 20 minutes of telephone follow-up twice per week for four weeks. The control group received only routine outpatient care. Self-care behaviour was measured by the Self-Care of Heart Failure Index at baseline, 4 weeks and 8 weeks after patients were enrolled. Quality of life was measure with the Minnesota Living with Heart Failure questionnaire

Study Design

Conditions

Heart Failure

Intervention

self-regulation programme

Status

Completed

Source

National Yang Ming University

Results (where available)

View Results

Links

Published on BioPortfolio: 2020-01-19T11:04:54-0500

Clinical Trials [3296 Associated Clinical Trials listed on BioPortfolio]

Hormone KLOTHO Level in Heart Failure Patients That Participate in Rehabilitation Programme

30 patients suffering from Heart Failure with Ejection Fraction less than 40% start Cardiac Rehabilitation Programme, serum KLOTHO Hormone level and other labs and Echo measurements will b...

Flow Regulation by Opening the Septum in Patients With Heart Failure Trial

To investigate the safety and efficacy of a novel atrial flow regulator (AFR) device in patients with heart failure and preserved ejection fraction.

“ALOFT – Aliskiren Observation of Heart Failure Treatment”: Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure

This study was designed to determine if patients, who have both high blood pressure and heart failure and are currently receiving drug treatment for heart failure, have an improvement in t...

Curing Atrial Fibrillation in Heart Failure

Heart failure is a condition that occurs when the heart muscle weakens and no longer contracts normally. Half of these patients have an irregularity of heart rhythm called atrial fibrilla...

Non Invasive Assessment of Heart Failure

1. To Identify the role of aldosterone antagonist in patients of heart failure with preserved ejection fraction. 2. Portray the health profile of heart failure patients admitted in...

PubMed Articles [11469 Associated PubMed Articles listed on BioPortfolio]

Update on pediatric heart failure.

This review highlights recent advances in the diagnosis and management of children with heart failure. We emphasize the clinical approach to patient care in the areas of acute decompensated heart fail...

Emotion regulation in patients with heart failure: Its relationship with depressive symptoms and rehospitalization.

To examine the role of emotion regulation and its relationship to mental and physical health in patients with heart failure (HF).

Differential Regulation of ANP and BNP in Acute Decompensated Heart Failure: Deficiency of ANP.

This study investigated the differential regulation of circulating atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in patients with acute decompensated heart failure (ADHF) and t...

Heart failure with preserved ejection fraction: the dark side of an old disease.

Heart failure is a global public health problem, with more than 37 million patients living with heart failure around the world. Heart failure with preserved ejection fraction is an increasingly common...

Evolution of mitral regurgitation in patients with heart failure referred to a tertiary heart failure clinic.

Medical and Biotech [MESH] Definitions

A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.

Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.

Heart failure caused by abnormal myocardial contraction during SYSTOLE leading to defective cardiac emptying.

Heart failure caused by abnormal myocardial relaxation during DIASTOLE leading to defective cardiac filling.

Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).

More From BioPortfolio on "Effects of a Self-regulation Program on Self-care Behaviour of Heart Failure Patients"

Quick Search

Searches Linking to this Trial